Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Neurodegenerative Disease Management|March 20, 2014
NMDA antagonists as Parkinson's disease therapy: disseminating the evidenceZsófia Majláth, László VécseiJournal of Neural Transmission (Vienna, Austria : 1996)|December 19, 2013
The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptorsZsófia Majláth, József Toldi, László VécseiTherapeutic Advances in Neurological Disorders|November 15, 2013
Kynurenines and other novel therapeutic strategies in the treatment of dementiaZsófia Majláth, János Tajti, László VécseiCNS & Neurological Disorders Drug Targets|April 30, 2015
Drug targets of migraine and neuropathy: treatment of hyperexcitabilityLászló Vécsei, Zsófia Majláth, Anna Balog, et al.Journal of Parkinson'S Disease|December 19, 2013
Mental disturbances in Parkinson's disease and related disorders: the role of excitotoxinsIzabella Obál, Zsófia Majláth, József Toldi, et al.Current Neuropharmacology|November 14, 2015
Memantine and Kynurenic Acid: Current Neuropharmacological AspectsZsófia Majláth, Nóra Török, József Toldi, et al.Current Medicinal Chemistry|February 14, 2016
Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine SystemZsófia Majláth, József Toldi, Ferenc Fülöp, et al.Expert Opinion on Biological Therapy|March 11, 2016
Promising therapeutic agents for the treatment of Parkinson's diseaseZsófia Majláth, Nóra Török, József Toldi, et al.Expert Opinion on Investigational Drugs|September 29, 2016
Investigational α-synuclein aggregation inhibitors: hope for Parkinson's diseaseNóra Török, Zsófia Majláth, Levente Szalárdy, et al.Pageof 2